CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.

Prescription of Neurontin (gabapentin) and other gabapentinoids has increased partly because they are viewed as a safer alternative to opioids.

Here’s what you missed this week on Managed Healthcare Executive.

During the COVID-19 pandemic, healthcare workers faced several mental health challenges, experiencing repeated exposure to life-threatening situations that increased their risk of PTSD and other trauma-related conditions.

Patient follow-up 10 years after hormone replacement therapy treatment revealed there were no long-term negative cognitive effects.

In a recent conversation with Greg Baker, CEO of AffirmedRx, the PBM professional outlined the company’s distinct approach in the PBM industry with MHE editors.

An intervention program that coaches patients in stress management and goal setting, along with a digital app, helped adolescents experience less distress and improved self-management behavior.

The campaign for hand eczema is the latest in a number of high-cost campaigns to raise awareness of dermatological conditions.

Gene therapies have a lot of potential to improve health outcomes for patients with life-threatening diseases but face a number of barriers that restrict access.

Identifying what is truly treatment resistant depression is difficult given all the factors that may influence how a person responds to treatment.

Produced in Chinese hamster ovary cells, Ziihera (zanidatamab-hrii) is the first HER2-targeted bispecific antibody treatment for patients with previously treated, unresectable or metastatic biliary tract cancer.

Kennedy's vaccines may give some Republican senators pause while Oz has an ally in Medicare Advantage plans.

After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.

The FDA has approved UCB's Bimzelx for moderate-to-severe hidradenitis suppurativa, offering a new treatment option for this painful autoimmune skin disease.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

Medicare fraud costs Americans about $60 billion each year and healthcare plans are stepping in spread awareness and stop criminals.

Mehmet Oz, M.D., is another unconventional pick by Trump and is perhaps another an indication that Trump intends to let his HHS secretary nominee, Robert F. Kennedy Jr., "go wild on health."

Patients with pulmonary arterial hypertension often experienced delays in obtaining a correct diagnosis.

A total of 17 lots are now part of the recall of Clonazepam because some cartons have the wrong strength on the label.

Relapsed or refractory acute leukemia with a KMT2A translocation currently has an overall survival rate of less than one year when treated with frontline therapies.

Researchers are currently enrolling participants to test the effectiveness of a rectal douche containing the antiretroviral drug tenofovir in a study that is expected to finish in January 2026.

Laser therapies may help with pain after a root canal, but a review of published studies shows their effectiveness can vary significantly. Further research is needed to identify the optimal approach.

In contrast to electroconvulsive therapy, patients are not sedated during the treatments. Studies of a protocol called accelerated intermittent theta-burst stimulation have produced positive results.

The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025, for reproxalap for patients with dry eye disease. Reproxalap also is being tested in allergic conjunctivitis.